Electronic Messaging Intervention Cuts Cardiovascular Risk in T2DM

This article originally appeared here.
Share this content:
Electronic Messaging Intervention Cuts Cardiovascular Risk in T2DM
Electronic Messaging Intervention Cuts Cardiovascular Risk in T2DM

WEDNESDAY, July 19, 2017 (HealthDay News) -- For patients with type 2 diabetes mellitus, a electronic messaging intervention is effective for reducing cardiovascular risk, according to a study published online July 12 in the Journal of Clinical Nursing.

Ronghua Fang, R.N., and Xuexue Deng, R.N., from the West China Hospital Sichuan University in Chengdu, conducted a convenience sample study with randomized group assignment to examine the effectiveness of an electronic messaging support service for management of cardiovascular risk factors in patients with type 2 diabetes. Participants completed surveys and underwent physical and laboratory evaluations, and were randomized to either receipt of electronic messages or a phone call. Intervention patients received appointment reminders and health information via electronic message. Intervention and control patients were followed-up every three months by telephone.

The researchers found that between-group differences were statistically significant in glycated hemoglobin, postprandial plasma glucose, postprandial insulin, total cholesterol, and low-density lipoprotein cholesterol. In intervention patients, there were significant decreases in levels of glycated hemoglobin, fasting plasma glucose, postprandial plasma glucose, fasting insulin, postprandial insulin, total cholesterol, and low-density lipoprotein cholesterol. Patients only followed by telephone had a significant decrease in systolic blood pressure.

"Regular smartphone communication had a favorable impact on cardiovascular risk factors in patients with type 2 diabetes mellitus," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths